Clinical trials
mCRPC clinical trials
Below are recruiting mcrpc clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06992232RecruitingPhase 2
Radiation or surgery plus hormone therapy for prostate cancer that has spread
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Nanjing, JiangsuAges 18–80 - NCT07002320RecruitingPhase 1/Phase 2
Testing SX-682 plus apalutamide for advanced prostate cancer
This trial tests a new combination of two drugs (SX-682 and apalutamide) for men with metastatic prostate cancer that is no longer responding to standard hormone therapy. The goal is to see if adding SX-682 can help apalutamide work better.
BellinzonaAges 18 years+ - NCT06943495RecruitingPhase 1
Personalized vs. standard dose of a targeted therapy for prostate cancer
This trial compares two ways of giving a radioactive drug (177Lu-PSMA-617) designed to find and destroy prostate cancer cells. It tests whether adjusting the dose based on your individual tumor’s activity works better than a fixed standard dose.
Québec, QuebecAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06659926Recruiting
Radium-select study for advanced prostate cancer
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
Amsterdam, North HollandAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06826768RecruitingPhase 1
Study of REGN5678 plus cemiplimab for advanced prostate cancer
This trial tests a combination of two drugs (REGN5678 and cemiplimab) for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to see if this new combination can help shrink the cancer or slow its growth.
Houston, TexasAges 18 years+ - NCT06801236RecruitingPhase 1
A new drug for advanced prostate cancer that has stopped responding to treatment
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Gilbert, ArizonaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Scottsdale, ArizonaAges 18–100 - NCT06615752RecruitingPhase 1/Phase 2
Green tea and quercetin with chemo for prostate cancer
This trial tests whether adding green tea extract and quercetin (a plant compound) to standard chemotherapy (docetaxel) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination is safe and works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Tuscon, ArizonaAges 18 years+ - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Orange, CaliforniaAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
Sacramento, CaliforniaAges 18 years+ - NCT06401980RecruitingPhase 2
Darolutamide for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
AarauAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT06190899RecruitingPhase 1/Phase 2
Testing gedatolisib plus darolutamide in advanced prostate cancer
This trial tests a new combination of two drugs, gedatolisib and darolutamide, in men with prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can help control the cancer when standard treatments have stopped working.
Detroit, MichiganAges 18 years+ - NCT06193486RecruitingPhase 1
T-Cell Therapy for Advanced Prostate Cancer with Bone Spread
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
Tampa, FloridaAges 18 years+ - NCT06155084RecruitingPhase 1/Phase 2
HP518 for advanced prostate cancer that has spread
This trial tests an oral drug called HP518 for men with a specific genetic change in their prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The goal is to see if HP518 can control the cancer.
Hefei, AnhuiAges 18 years+ - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Orange, CaliforniaAges 18 years+
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mcrpc?
- Yes. Clin2 currently lists 87 recruiting mcrpc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mcrpc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mcrpc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.